On July 3, WuXi XDC rose 3.91% in regular trading, trading at HK$60.1/share, with turnover of HK$126 million. The rally was driven by continued strength in the CXO sector combined with the company's ongoing share buyback program and favorable broker coverage.

On the industry front, CXO peers extended their recent momentum, with GenScript Biotech gaining 3.65% and XtalPi rising 3.48%, reflecting broad sector linkage. WuXi XDC previously announced a share repurchase plan of up to US$100 million using internal funds, with the appointed trustee having already purchased 5.7 million shares at an average price of HK$57.3 during May, spending approximately HK$327 million. BOCOM International highlighted WuXi XDC as a top pick among high-growth-track leaders with strong investment value, while Guotai Junan maintained an Overweight rating with a target price of HK$84.38. The company's backlog stands at approximately US$1.489 billion, representing 50.3% year-over-year growth, underpinning strong earnings visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)